Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Neuraxis Q3 2026 Results: Net Loss of $6.55M, Loss Widens

Neuraxis, Inc. reported a significant increase in net sales to $5.56 million for the nine months ended September 30, 2026, compared to $2.60 million in the prior year. However, the company experienced a widened net loss of $10.39 million due to a substantial rise in general and administrative expenses, which nearly doubled to $11.91 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue2.00.8
Gross profit1.80.7
Net income-6.5-2.1
EPS (diluted, $ a share)$-0.52$-0.24

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+149.9%
Gross margin86.6%
Operating margin-324.4%
Source

10-Q filed with the SEC, NYSE: NRXS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Neuraxis, INC: key numbers

Share price
$4.80Close, Nov 16
Market cap
$68.1M
Shares outstanding
14.19MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Electromedical & Electrotherapeutic ApparatusSIC 3845

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Neuraxis, INC

All →
5:00 PM ET 8-K
Dividend

Neuraxis Dividend

Neuraxis, Inc. declared a third quarter 2026 stock dividend for its Series B Preferred Stock, payable in approximately 81,339 shares of common stock. The dividend is payable on October 30, 2026, to holders of record as of October 26, 2026, with the share count calculated based on a price of $2.38 per share.

Term
Q3 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.